These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 7655155)
21. Cellular uptake and trafficking of antisense oligonucleotides. Crooke ST; Wang S; Vickers TA; Shen W; Liang XH Nat Biotechnol; 2017 Mar; 35(3):230-237. PubMed ID: 28244996 [TBL] [Abstract][Full Text] [Related]
22. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA. Nakano M; Aoki K; Matsumoto N; Ohnami S; Hatanaka K; Hibi T; Terada M; Yoshida T Mol Ther; 2001 Apr; 3(4):491-9. PubMed ID: 11319909 [TBL] [Abstract][Full Text] [Related]
23. Antisense effects in the cell nucleus: modification of splicing. Kole R; Sazani P Curr Opin Mol Ther; 2001 Jun; 3(3):229-34. PubMed ID: 11497345 [TBL] [Abstract][Full Text] [Related]
24. Antisense approaches to the gene therapy of cancer--'Recnac'. Gibson I Cancer Metastasis Rev; 1996 Sep; 15(3):287-99. PubMed ID: 9034592 [TBL] [Abstract][Full Text] [Related]
25. [Antisense hypoxia inducible factor-1alpha and B7-1 combination gene therapy for mouse lymphoma]. Sun XY; Meng FQ; Jiang HC; Qiao HQ; Li W Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):404-7. PubMed ID: 16188124 [TBL] [Abstract][Full Text] [Related]
26. Antisense oligonucleotides as inhibitors of genes that regulate AP-1: pharmacology and clinical development. Dean NM; McKay RA; Holmlund J Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):147-51. PubMed ID: 9593055 [No Abstract] [Full Text] [Related]
27. Design and Selection of Antisense Oligonucleotides Targeting Transforming Growth Factor Beta (TGF-β) Isoform mRNAs for the Treatment of Solid Tumors. Jaschinski F; Korhonen H; Janicot M Methods Mol Biol; 2015; 1317():137-51. PubMed ID: 26072406 [TBL] [Abstract][Full Text] [Related]
28. Encapsulation of nucleic acids and opportunities for cancer treatment. Brannon-Peppas L; Ghosn B; Roy K; Cornetta K Pharm Res; 2007 Apr; 24(4):618-27. PubMed ID: 17372693 [TBL] [Abstract][Full Text] [Related]
29. Cancer gene therapy: Part 2. Candidate transgenes and their clinical development. Harrington KJ; Melcher AA; Bateman AR; Ahmed A; Vile RG Clin Oncol (R Coll Radiol); 2002 Apr; 14(2):148-69. PubMed ID: 12069125 [No Abstract] [Full Text] [Related]
30. Antisense therapy in oncology: new hope for an old idea? Tamm I; Dörken B; Hartmann G Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935 [TBL] [Abstract][Full Text] [Related]
31. Antisense oligonucleotide therapy in the management of bladder cancer. So A; Rocchi P; Gleave M Curr Opin Urol; 2005 Sep; 15(5):320-7. PubMed ID: 16093856 [TBL] [Abstract][Full Text] [Related]
38. Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity. Ohnami S; Matsumoto N; Nakano M; Aoki K; Nagasaki K; Sugimura T; Terada M; Yoshida T Cancer Res; 1999 Nov; 59(21):5565-71. PubMed ID: 10554036 [TBL] [Abstract][Full Text] [Related]
39. European School of Oncology Task Force Papers: gene therapy--a future in cancer management? Antisense therapy for malignant disease. O'Brien SG; Kirkland MA; Goldman JM Eur J Cancer; 1994; 30A(8):1160-4. PubMed ID: 7654449 [No Abstract] [Full Text] [Related]
40. [The application of antisense technology in ophthalmology]. Guo Y; Ge J Yan Ke Xue Bao; 1998 Jun; 14(2):108-15. PubMed ID: 12580046 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]